Author

H. Medjahed

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 11 Immunology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 17 Research Focus:host-pathogen & immune response· 15 Organism:human· 15 Assay:proteomics· 14 Research Focus:cell type annotation· 5 Research Focus:clustering· 3 Research Focus:differential expression· 3 Assay:flow cytometry· 3

Frequent Co-Authors

A. Finzi· 18 shared J. Richard· 14 shared G. Gendron-Lepage· 12 shared J. Prevost· 11 shared R. Gasser· 11 shared S. Ding· 10 shared G. Beaudoin-Bussieres· 9 shared G. Goyette· 9 shared

Activity by Year

2020-2024 · peak 9/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

18 shared papersMicrobiology

A. Finzi

Mutual co-authors in cluster

Author profile →

18 papers

Recent·Most cited

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission

M. Benlarbi, S. Ding, E. Belanger, A. Tauzin, R. Poujol, H. Medjahed, O. El Ferri, Y. Bo, C. Bourassa, J. Hussin, J. Fafard, M. Pazgier, I. Levade, C. Abrams, M. Cote, A. Finzi

This study examines how temperature affects Spike-ACE2 interactions in Omicron subvariants and links these interactions to viral transmission efficiency.

bioRxiv · Jan 20, 2024Microbiology

Piperidine CD4-mimetic compounds expose vulnerable Env epitopes sensitizing HIV-1-infected cells to ADCC

S. Ding, W. D. Tolbert, H. Zhu, D. Lee, T. Higgins, X. Zhao, D. Nguyen, R. Sherburn, J. Richard, G. Gendron-Lepage, H. Medjahed, M. Mohammadi, C. Abrams, M. Pazgier, A. B. Smith, A. Finzi

The paper describes piperidine-based CD4-mimetic compounds that expose HIV-1 Env epitopes, increasing sensitivity to ADCC by targeting Asp368.

bioRxiv · Mar 23, 2023 · PreprintImmunology

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile

G. Sannier, A. Nicolas, M. Dube, L. Marchitto, M. Nayrac, O. Tastet, A. Tauzin, R. Lima-Barbosa, M. Laporte, R. Cloutier, A. S. Flores, M. Boutin, S. Y. Gong, M. Benlarbi, S. Ding, , D. E. Kaufmann

bioRxiv · Sep 5, 2022Immunology

Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity

A. Laumaea, L. Marchitto, G. Beaudoin-Bussieres, S. Ding, R. Gasser, D. Chatterjee, G. Gendron-Lepage, H. Medjahed, H.-C. Chen, A. B. Smith, H. Ding, J. C. Kappes, B. H. Hahn, F. Kirchhoff, J. Richard, , A. Finzi

The paper shows that small CD4 mimetics expose ADCC epitopes on HIV-1-infected macrophages, making them susceptible to antibody-dependent cellular cytotoxicity.

bioRxiv · Jun 30, 2022Microbiology

SARS-CoV-2 accessory protein ORF8 decreases antibody-dependent cellular cytotoxicity

G. Beaudoin-Bussieres, A. Arduini, C. Bourassa, H. Medjahed, G. Gendron-Lepage, J. Richard, Q. Pan, Z. Wang, C. Liang, A. Finzi

This study shows that SARS-CoV-2 accessory protein ORF8 reduces antibody-dependent cellular cytotoxicity by binding CD16a and decreasing CD16 surface levels on monocytes and NK cells.

bioRxiv · Mar 30, 2022Immunology

HIV-1 Vpu restricts Fc-mediated effector functions in vivo

J. Prevost, S. P. Anand, J. K. Rajashekar, J. Richard, G. Goyette, H. Medjahed, G. Gendron-Lepage, H.-C. Chen, Y. Chen, J. A. Horwitz, M. W. Grunst, S. Zolla-Pazner, B. F. Haynes, D. R. Burton, R. A. Flavell, , A. Finzi

This study shows that HIV-1 Vpu reduces nnAb recognition and ADCC resistance, with nnAb Fc-effector functions dependent on Env's open conformation.

bioRxiv · Feb 21, 2022Microbiology

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses

D. Chatterjee, A. Tauzin, L. Marchitto, S. Y. Gong, M. Boutin, C. Bourassa, G. Beaudoin-Bussieres, Y. Bo, S. Ding, A. Laumaea, D. Vezina, J. Perreault, L. Gokool, C. Morrisseau, P. Arlotto, , A. Finzi

This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.

bioRxiv · Dec 21, 2021Microbiology

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

M. Nayrac, M. Dube, G. Sannier, A. Nicolas, L. Marchitto, O. Tastet, A. Tauzin, N. Brassard, G. Beaudoin-Bussieres, D. Vezina, S. Y. Gong, M. Benlarbi, R. Gasser, A. Laumaea, C. Bourassa, , D. E. Kaufmann

The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.

bioRxiv · Dec 18, 2021Immunology

Detection of the HIV-1 accessory proteins Nef and Vpu by flow cytometry represents a new tool to study their functional interplay within a single infected CD4+ T cell

J. Prevost, J. Richard, R. Gasser, H. Medjahed, F. Kirchhoff, B. H. Hahn, J. C. Kappes, C. Ochsenbauer, R. Duerr, A. Finzi

The paper develops a flow cytometry method to detect HIV-1 Nef and Vpu in CD4+ T cells, showing Vpu cannot compensate for Nef absence in ADCC susceptibility.

bioRxiv · Nov 3, 2021Microbiology

HIV-1 envelope glycoproteins proteolytic cleavage protects infected cells from ADCC mediated by plasma from infected individuals

J. Prevost, H. Medjahed, D. Vezina, H.-C. Chen, B. H. Hahn, A. B. Smith, A. Finzi

This study shows that HIV-1 envelope glycoproteins proteolytic cleavage protects infected cells from ADCC by reducing the exposure of uncleaved Env to non-neutralizing antibodies.

bioRxiv · Oct 26, 2021Microbiology

Across functional boundaries: making non-neutralizing antibodies to neutralize HIV-1 and mediate Fc-mediated effector killing of infected cells

J. Richard, D. Nguyen, W. D. Tolbert, R. Gasser, s. ding, D. Vezina, S. Yu Gong, J. Prevost, G. Gendron-Lepage, H. Medjahed, S. Gottumukkala, A. Finzi, M. Pazgier

This paper designs Ab-CD4 chimeric proteins that open HIV-1 Env trimers to expose non-neutralizing epitopes, enabling both neutralization and ADCC against HIV-1.

bioRxiv · Aug 13, 2021Immunology

Contribution of single mutations to selected SARS-CoV-2 emerging variants Spike antigenicity

S. Y. Gong, D. Chatterjee, J. Richard, J. Prevost, A. Tauzin, R. Gasser, Y. Bo, D. Vezina, G. Goyette, G. Gendron-Lepage, H. Medjahed, M. Roger, M. Cote, A. Finzi

The paper evaluates how single mutations in SARS-CoV-2 Spike protein affect antigenicity and ACE2 binding in emerging variants.

bioRxiv · Aug 4, 2021Microbiology

Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy

I. Ullah, J. Prevost, M. S. Ladinsky, H. Stone, M. Lu, S. P. Anand, G. Beaudoin-Bussieres, K. Symmes, M. Benlarbi, S. Ding, R. Gasser, C. Fink, Y. Chen, A. Tauzin, G. Goyette, , P. D. Uchil

This study uses live imaging to show that neutralizing antibodies against SARS-CoV-2 need both Fab and Fc functions to effectively prevent and resolve infection in mice.

bioRxiv · Mar 22, 2021Immunology

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

A. Tauzin, M. Nayrac, M. Benlarbi, S. Y. Gong, R. Gasser, G. Beaudoin-Bussieres, N. Brassard, A. Laumaea, D. Vezina, J. Prevost, S. P. Anand, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, , A. Finzi

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

bioRxiv · Mar 18, 2021 · PreprintImmunology

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

S. P. Anand, J. Prevost, M. Nayrac, G. Beaudoin-Bussieres, M. Benlarbi, R. Gasser, N. Brassard, A. Laumaea, S. Y. Gong, C. Bourassa, E. Brunet-Ratnasingham, H. Medjahed, G. Gendron-Lepage, G. Goyette, L. Gokool, , A. Finzi

This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.

bioRxiv · Jan 25, 2021Microbiology

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

R. Gasser, M. Cloutier, J. Prevost, C. Fink, E. Ducas, S. Ding, N. Dussault, P. Landry, T. Tremblay, A. Laforce-Lavoie, A. Lewin, G. Beaudoin-Bussieres, A. Laumaea, H. Medjahed, C. Larochelle, , A. Finzi

This study shows that IgM plays a major role in neutralizing SARS-CoV-2 in convalescent plasma, with its depletion causing the greatest loss of neutralizing activity.

bioRxiv · Oct 9, 2020Microbiology

Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization

S. Ding, A. Laumaea, R. Gasser, H. Medjahed, M. Pancera, L. Stamatatos, A. McGuire, R. Bazin, A. Finzi

bioRxiv · Sep 8, 2020Microbiology

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

J. Prevost, R. Gasser, G. Beaudoin-Bussieres, J. Richard, R. Duerr, A. Laumaea, S. P. Anand, G. Goyette, M. Benlarbi, S. Ding, H. Medjahed, A. Lewin, J. Perreault, T. Tremblay, G. Gendron-Lepage, , A. Finzi

This study evaluates humoral responses against SARS-CoV-2 Spike in 106 infected individuals, finding persistent RBD-specific IgG and declining neutralizing activity over time.

bioRxiv · Jun 8, 2020Microbiology